Dr Sudipto Mukherjee: Rethinking Clinical Management for Patients With ISM
Population-level data highlight varied risk profiles among patients with indolent systemic mastocytosis (ISM), highlighting the need for individualized treatment approaches, according to Sudipto Mukherjee, MD, PhD, MPH, a physician in the department of hematology and medical oncology at Cleveland Clinic.
COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy
Miriam J. Atkins, MD, FACP, president of the Community Oncology Alliance, discusses the impact of pharmacy benefit managers (PBMs) on health care costs and offers potential ways to remedy certain CMS decisions that negatively affect oncologists and their patients.
Bevey Miner: Unpacking the 21st Century Cures Act, the Role of Open Comment Periods
Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the complex landscape of proposed health care rules, and the potential impact of CMS' Advancing Interoperability and Prior Authorizations Rule.
Dr Sudipto Mukherjee Discusses Survival Outcomes Data in US Patients With ISM
Sudipto Mukherjee, MD, PhD, MPH, hematology and medical oncology, Cleveland Clinic, suggests that some patients with indolent systemic mastocytosis (ISM) may be progressing at a faster rate than expected, and will need to be monitored and started on appropriate therapies.
Bevey Miner Talks Interoperability in Digital Health Policy
Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the historic progression of health information technology and the role interoperability plays in secure exchanging of patient data.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.